Current Cancer Drug Targets

Ruiwen Zhang 
Texas Tech University Health Sciences Center
1300 Coulter Drive
Amarillo, TX 79106


The Crosstalk of RAS with the TGF-β Family During Carcinoma Progression and its Implications for Targeted Cancer Therapy

Author(s): M. Grusch, M. Petz, T. Metzner, D. Ozturk, D. Schneller, W. Mikulits.


Both RAS and transforming growth factor (TGF)-β signaling cascades are central in tumorigenesis and show synergisms depending on tumor stage and tissue context. In this review we focus on the interaction of RAS subeffector proteins with signaling components of the TGF-β family including those of TGF-βs, activins and bone morphogenic proteins. Compelling evidence indicates that RAS signaling is essentially involved in the switch from tumor-suppressive to tumor-promoting functions of the TGF-β family leading to enhanced cancer growth and metastatic dissemination of primary tumors. Thus, the interface of these signaling cascades is considered as a promising target for the development of novel cancer therapeutics. The current pharmacological anti-cancer concepts combating the molecular cooperation between RAS and TGF-β family signaling during carcinoma progression are critically discussed.

Keywords: Activin, BMP, cancer progression, RAS, Smad, targeted therapy, TGF-β, neoangiogenesis, mesenchymal transition (EMT), RAL proteins, anti-Muellerian hormone (AMH), TGFBRII, adaptor protein ShcA, myofibroblasts, pro-oncogenic TGF-, NADPH oxidase, pancreatic adenocarcinoma, JNK, pSmad3C, mutant-p53, transcriptional control, LIM kinase 1, EMT, pancreatic cancer, NF-B, neo-angiogenesis, ActRIIB, FOXH1, MH

Order Reprints Order Eprints Rights & PermissionsPrintExport

Article Details

Year: 2010
Page: [849 - 857]
Pages: 9
DOI: 10.2174/156800910793357943
Price: $58